Arrowhead Pharma Q3 2024 Revenue $0 Down From $15.825M YoY
Portfolio Pulse from Benzinga Newsdesk
Arrowhead Pharmaceuticals reported a significant decline in Q3 2024 revenue, dropping to $0 from $15.825 million year-over-year.
August 08, 2024 | 8:09 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Arrowhead Pharmaceuticals reported a significant decline in Q3 2024 revenue, dropping to $0 from $15.825 million year-over-year.
The drastic drop in revenue from $15.825 million to $0 is a significant negative indicator for Arrowhead Pharmaceuticals. This could lead to a decline in investor confidence and a potential drop in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100